<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942290</url>
  </required_header>
  <id_info>
    <org_study_id>M15-531</org_study_id>
    <secondary_id>2016-001657-41</secondary_id>
    <nct_id>NCT02942290</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating
      venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS
      comprising a dose-escalation portion and a safety expansion portion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2017</start_date>
  <completion_date type="Anticipated">October 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of venetoclax</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Maximum plasma concentration (Cmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt for venetoclax</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of venetoclax</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Time to Cmax (peak time, Tmax) of venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC[0 to infinity] for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Area under the plasma concentration-time curve from Time 0 to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose (RPTD) and dosing schedule of venetoclax in combination with azacitidine</measure>
    <time_frame>Measured from Day 1 until Day 28 per dose level.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t[1/2]) for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Terminal elimination half-life (t[1/2]) for azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Maximum plasma concentration (Cmax) of azacitidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC[0-24] for venetoclax</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>AUC over a 24-hour dose interval (AUC[0-24]) for venetoclax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for azacitidine</measure>
    <time_frame>Up to 32 days</time_frame>
    <description>Time to Cmax (peak time, Tmax) of azacitidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Measured from the date of first response (CR or PR) to the earliest documentation of progressive disease (PD) and for an anticipated maximum duration of 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of red blood cell (RBC) transfusion independence</measure>
    <time_frame>Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Percentages of participants who become RBC transfusion-independent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Measured from the date of first dose of study drug to the date of earliest disease progression or death, and for an anticipated maximum duration of 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Measured from the date of first dose of study drug to the date of death, and for up to 5 years after the last subject is enrolled.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement (HI) rate</measure>
    <time_frame>Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Percentages of participants with HI (erythroid/platelet/neutrophil responses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of platelet (PLT) transfusion independence</measure>
    <time_frame>Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Percentages of participants who become platelet transfusion-independent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Measured from the date of the first dose of study drug to the date of earliest disease progression, death, or initiation of new non-protocol-specified anti-MDS therapy without documented progression and for up to 5 yrs after the last subject is enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to transformation to acute myeloid leukemia (AML)</measure>
    <time_frame>Measured from the date of first dose of study drug to the date of documented AML transformation, defined as a bone marrow blast count greater than or equal to 20%, and for an anticipated maximum duration of 24 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bone marrow blast response</measure>
    <time_frame>Measured from Screening as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Percentages of participants with a bone marrow blast response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Complete response rate will be defined as the proportion of subjects who achieved a complete response per the International Working Group (IWG) 2006 criteria for Myelodysplastic Syndromes (MDS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Measured from Cycle 1 Day 1 as long as the subject continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.</time_frame>
    <description>ORR (equals the sum of rates of complete remission [CR] + partial remission [PR]) of venetoclax in combination with azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cytogenetic response</measure>
    <time_frame>Measured from Screening as long as the subject continues to benefit or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.</time_frame>
    <description>Percentages of participants with cytogenetic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>Measured from the first dose of study drug to start of new non-protocol specified MDS therapy, and for up to 5 years after the last subject is enrolled.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)</condition>
  <arm_group>
    <arm_group_label>Venetoclax + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Powder for injection; taken subcutaneously or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 &amp; Days 1-2 of Week 2 of 28 day cycle.</description>
    <arm_group_label>Venetoclax + Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Venetoclax + Azacitidine</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have documented diagnosis of de novo MDS with:

               -  International Prognostic Scoring System (IPSS) risk categories Int-2 or High
                  (IPSS overall score ≥ 1.5) and

               -  Presence of greater than or equal to 5% and less than 20% bone marrow blasts per
                  bone marrow

          -  Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to
             2.

          -  Participant is not a candidate to undergo intensive chemotherapy or allogeneic
             hematopoietic stem cell transplantation (HSCT).

        Exclusion Criteria:

          -  Participant has received prior therapy for MDS. (Prior supportive care in form of
             transfusions or growth factors, etc., is not considered prior therapy.)

          -  Participant has received prior therapy with a BH3 mimetic.

          -  Participant has a diagnosis other than previously untreated de novo MDS with IPSS risk
             categories Int-2 or High, including:

               -  MDS with IPSS risk categories Low or Int-1 (overall IPSS score &lt; 1.5)

               -  Therapy-related MDS (t-MDS)

               -  MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)

               -  MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic
                  myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and
                  unclassifiable MDS/MPN

          -  Participant has received allogeneic HSCT or solid organ transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Arizona Cancer Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719-1478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Kansas Med Ctr</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Maryland School Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Wo</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh MC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation &amp; Gen Hos</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Clinic</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu</name>
      <address>
        <city>Nantes CEDEX 1</city>
        <state>Pays-de-la-Loire</state>
        <zip>44042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wurttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle (S</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi</name>
      <address>
        <city>Florence</city>
        <state>Firenze</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP Romano Umberto I</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Univ Hosp</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Higher-Risk (HR) Myelodysplastic Syndromes (MDS)</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes (MDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

